通过药理动力学预测,分子对接,动态模拟和实验验证实,通过阿尔茨海默氏病确定Magnolia officinalis的潜在化合物

相关实验视频

Updated: Jun 10, 2025

Cellular Membrane Affinity Chromatography Columns to Identify Specialized Plant Metabolites Interacting with Immobilized Tropomyosin Kinase Receptor B

Published on: January 19, 2022

2.5K

Kumju Youn^1,2, Mira Jun^1,2,3

¹Department of Food Science and Nutrition, Dong-A University, Busan 49315, Republic of Korea.

International journal of molecular sciences

|October 16, 2024

概括

红醇是Magnolia officinalis中的一种化合物,有效地抑制了与阿尔茨海默氏症有关的多种酶.

科学领域:

神经科学是一个神经科学.
药理学药理学是指药理学的学科.
生物化学生化学

背景情况:

氨基酸β (Aβ) 蛋白沉积驱动阿尔茨海默病 (AD) 的进展.
准Aβ聚合和翻译后修改是抗AD的关键策略.
贝塔位点APP切割酶1 (BACE1),乙胆酶 (AChE),糖原合成酶激酶-3β (GSK-3β) 和谷氨基基酶 (QC) 在AD病变发生过程中至关重要.

研究的目的:

为了确定阿尔茨海默病的新型多位抑制剂.
调查Magnolia officinalis的化合物作为抗老年痴呆症药物的潜力.
评价霍诺基作为关键AD相关酶的多目标抑制剂.

主要方法:

在*Magnolia officinalis*的化合物的选和实验验证.
进行对接和分子动力学 (MD) 模拟,以评估Honokiol的抑制潜力.
酶抑制试验测定了对BACE1,ACHE,GSK-3β和QC的红醇的IC50值.

主要成果:

霍诺基奥尔作为一种具有药物相似性,穿透血脑屏障和安全性的结构而出现.
霍诺基奥尔证明了BACE1,ACHE,GSK-3β和QC的强有力的多目标抑制.
霍诺基奥尔的IC50值在6-90μM之间,表现优于一些单抑制剂.

结论:

霍诺基奥尔是第一个被发现的多酶抑制剂,具有对AD的有利药理动力学和安全性.
霍诺基奥尔的抑制作用涵盖了Aβ的过度生产,聚合和翻译后修饰.
霍诺基为设计抗阿尔茨海默病多位抑制剂提供了一个新的结构模板.

关键词:

这就是阿切.阿尔茨海默氏症是阿尔茨海默氏症的一种疾病.亚博体育在线娱乐亚博体育在线娱乐在BACE1中获得了BACE1学位.这是GSK-3ββ.在QC中,QC是QC.在这里,我们是Honokiol.

相关概念视频

01:26

Alzheimer's Disease: Overview

449

Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...

449

01:22

Alzheimer's Disease: Treatment

166

Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...

166